Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study

NCT02587884 is registered in ClinicalTrials.gov with Eastern Hepatobiliary Surgery Hospital as lead sponsor.

NCT NCT02587884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02587884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
Not reported
Completion date
December 31, 2017
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma